A pivotal confirmatory study of VGX-3100 to treat cervical dysplasia caused by human papillomavirus (HPV)

Trial Profile

A pivotal confirmatory study of VGX-3100 to treat cervical dysplasia caused by human papillomavirus (HPV)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs VGX 3100 (Primary)
  • Indications Cervical dysplasia; Cervical intraepithelial neoplasia; Human polyomavirus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms REVEAL 2
  • Sponsors Inovio Pharmaceuticals
  • Most Recent Events

    • 06 Jul 2017 New trial record
    • 08 Jun 2017 According to an Inovio Pharmaceuticals media release, both REVEAL 1 and REVEAL 2 studies will be conducted in parallel. Mark Einstein is Principal Investigator for the studies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top